Macquarie tips CSL shares to hit $500
Alex GluyasMarkets reporter
Updated
CSL’s share price could almost double to $500 as earnings and margins at its massive blood plasma business rise over the next three years, Macquarie says.
The investment bank’s analysts, in a detailed 55-page note to clients, outlined their bullish view on the prospects of the country’s largest biotechnology group, suggesting CSL would come through a difficult period, during which its share price has suffered.
Loading...
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Equity markets
Fetching latest articles